Process Excellence in the Pharmaceutical Industry
Add bookmarkWe respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.
In the past, value creation was mainly based on intellectual property, market exclusivity and the blockbuster business model was the major source of cash.
Today, the reality is characterised by:
-
Shrinking research
-
Development productivity, and
-
Cost reduction initiatives
This is mostly driven by governmental pressure, shifting global growth, increased regulatory requirements and loss of market exclusivity for many of the blockbuster drugs. Despite the steadily increasing pressure, the industry remains optimistic. However, it still needs to find new solutions to fundamental strategic issues.
Based on pharmaceutical and biotechnology data from PEX Network's biennial State of
the Industry Survey. The following infographic created by Pharma IQ is a summary results
that will enable you to get a better understanding emerging trends in process excellence in the pharmaceutical and biotechnology industries. Discover which process excellence methodologies are being employed by pharmaceutical companies, annual budgets for process excellence within the pharmaceutical industry, the number of full time resources devoted to process excellence and how success is measured.
[inlinead]
